242 related articles for article (PubMed ID: 29610327)
1. Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk.
Ntai I; Fornelli L; DeHart CJ; Hutton JE; Doubleday PF; LeDuc RD; van Nispen AJ; Fellers RT; Whiteley G; Boja ES; Rodriguez H; Kelleher NL
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4140-4145. PubMed ID: 29610327
[TBL] [Abstract][Full Text] [Related]
2. Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling.
Adams LM; DeHart CJ; Drown BS; Anderson LC; Bocik W; Boja ES; Hiltke TM; Hendrickson CL; Rodriguez H; Caldwell M; Vafabakhsh R; Kelleher NL
J Biol Chem; 2023 Jan; 299(1):102768. PubMed ID: 36470426
[TBL] [Abstract][Full Text] [Related]
3. Precise Characterization of KRAS4B Proteoforms by Combining Immunoprecipitation with Top-Down Mass Spectrometry.
Adams LM; DeHart CJ; Kelleher NL
Methods Mol Biol; 2021; 2262():47-64. PubMed ID: 33977470
[TBL] [Abstract][Full Text] [Related]
4. Production and Membrane Binding of N-Terminally Acetylated, C-Terminally Farnesylated and Carboxymethylated KRAS4b.
Messing S; Agamasu C; Drew M; DeHart CJ; Stephen AG; Gillette WK
Methods Mol Biol; 2021; 2262():105-116. PubMed ID: 33977473
[TBL] [Abstract][Full Text] [Related]
5. FLAG-KRAS4B as a Model System for KRAS4B Proteoform and PTM Evaluation by Mass Spectrometry.
D'Ippolito RA; Scheidemantle GM; Smith BP; Powell K; Eury S; Neish A; Mehalko J; Beaumont L; Fer N; Wall V; Burgan W; Maciag AE; Esposito D; DeHart CJ
Methods Mol Biol; 2024; 2797():299-322. PubMed ID: 38570469
[TBL] [Abstract][Full Text] [Related]
6. Organization of Farnesylated, Carboxymethylated KRAS4B on Membranes.
Barklis E; Stephen AG; Staubus AO; Barklis RL; Alfadhli A
J Mol Biol; 2019 Sep; 431(19):3706-3717. PubMed ID: 31330153
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.
Dharmaiah S; Bindu L; Tran TH; Gillette WK; Frank PH; Ghirlando R; Nissley DV; Esposito D; McCormick F; Stephen AG; Simanshu DK
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6766-E6775. PubMed ID: 27791178
[TBL] [Abstract][Full Text] [Related]
8. In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.
Riffo-Campos ÁL; Castillo J; Vallet-Sánchez A; Ayala G; Cervantes A; López-Rodas G; Franco L
Oncol Rep; 2016 Dec; 36(6):3627-3634. PubMed ID: 27805251
[TBL] [Abstract][Full Text] [Related]
9. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
10. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
11. KRAS Prenylation Is Required for Bivalent Binding with Calmodulin in a Nucleotide-Independent Manner.
Agamasu C; Ghirlando R; Taylor T; Messing S; Tran TH; Bindu L; Tonelli M; Nissley DV; McCormick F; Stephen AG
Biophys J; 2019 Mar; 116(6):1049-1063. PubMed ID: 30846362
[TBL] [Abstract][Full Text] [Related]
12. The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo.
Cruz-Nova P; Schnoor M; Correa-Basurto J; Bello M; Briseño-Diaz P; Rojo-Domínguez A; Ortiz-Mendoza CM; Guerrero-Aguirre J; García-Vázquez FJ; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
BMC Cancer; 2018 Nov; 18(1):1056. PubMed ID: 30382908
[TBL] [Abstract][Full Text] [Related]
13. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
[TBL] [Abstract][Full Text] [Related]
14. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
Ye H; Liu Y; Wu K; Luo H; Cui L
Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
[TBL] [Abstract][Full Text] [Related]
15. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells.
Doubleday PF; Fornelli L; Ntai I; Kelleher NL
FEBS J; 2021 Dec; 288(23):6683-6699. PubMed ID: 34227245
[TBL] [Abstract][Full Text] [Related]
17. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Salmón M; Paniagua G; Lechuga CG; Fernández-García F; Zarzuela E; Álvarez-Díaz R; Musteanu M; Guerra C; Caleiras E; Muñoz J; Ortega S; Drosten M; Barbacid M
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301865
[TBL] [Abstract][Full Text] [Related]
18. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
20. Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein.
Agamasu C; Frank P; Perkins S; Waybright T; Messing S; Gillette W; Stephen AG
J Vis Exp; 2020 Jan; (155):. PubMed ID: 32009649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]